尿激酶溶栓治疗急性心肌梗塞在基层医疗机构开展的意义

Significance of urokinase thrombolysis in treatment of acute myocardial infarction in primary medical institutions

目的探讨在基层医疗机构应用尿激酶溶栓治疗急性心肌梗塞的用药剂量和疗效。方法选取2012年3月至2013年3月我院共收治的40例急性心肌梗塞患者为研究对象,将上述患者随机平均分为两组,两组患者均使用尿激酶溶栓进行治疗。对照组使用尿激酶注射液2万U/kg,观察组使用尿激酶注射液3万U/kg,观察其临床疗效。结果观察组溶栓患者死亡率为5.00%,对照组溶栓患者死亡率为40.00%,两者比较差异明显,具有统计学意义(P<0.05)。结论在基层医院使用尿激酶溶栓治疗急性心肌梗塞是一种行之有效的方法,不仅溶栓再通率高,还利于减轻患者经济负担,有临床推广的意义。

Objective To investigate the dosage and efficacy of urokinase thrombolysis in the treatment of acute myocardial infarction in primary medical institutions. Methods Forty patients with acute myocardial infarction admitted to our hospital from March 2012 to March 2013 were included in the study. These patients were randomly and equally divided into control group and observation group. The control group received urokinase injection 20000 U/kg, while the observation group received urokinase injection 30000 U/kg. The clinical outcomes of the two groups were assessed and compared. Results The observation group had a significantly lower mortality than the control group （5.00% vs 40.00%, P﹤0.05）. Conclusion Urokinase thrombolysis is an effective method for treating acute myocardial infarction in primary hospitals. This therapy can increase recanalization rate and reduce the economic burden of patients and holds promise for clinical application.